(opens in a new window)

Avery D Posey, PhD

Assistant Professor of Pharmacology

  • Director, Equal Opportunity Engagement, Center for Cellular Immunotherapy, Perelman School of Medicine, University of Pennsylvania

Department: Systems Pharmacology and Translational Therapeutics


Graduate Group Affiliations


Contact Information

PCAM SPE 8-106
3400 Civic Center Blvd.
Philadelphia, PA 19104
Email: aposey@pennmedicine.upenn.edu


I3H Keywords

  • Tumor Microenvironment

Education

  • B.S. (Biochemistry and Molecular Biology)
    University of Maryland, Baltimore County (UMBC), Baltimore, MD, 2005
  • B.S. (Bioinformatics and Computational Biology)
    University of Maryland, Baltimore County (UMBC), Baltimore, MD, 2005
  • PhD (Genetics)
    The University of Chicago, Chicago, IL, 2011

Post-Graduate Training

  • Postdoctoral Fellow
    Department of Pathology and Laboratory Medicine, University of Pennsylvania (Advisor: Carl H. June), 2011 - 2016

Description of ITMAT Expertise

Chimeric antigen receptor (CAR) T cells, cancer immunotherapy, glycans

Selected Publications

  • Schwab RD, Hong SA, Bi X, Degaramo DA, Faruqi A, Brookens SK, Keane JT, Liu F, Musunuru K, Rader DJ, Posey AD Jr. : OxLDL-targeted Chimeric Antigen Receptor T Regulatory Cells Reduce Atherosclerotic Plaque Development bioRxiv Jan 2025
  • Posey AD Jr, Young RM, June CH. : Future perspectives on engineered T cells for cancer Trends Cancer 10(8) : 687-695, Aug 2024
  • Patel RP, Ghilardi G, Zhang Y, Chiang YH, Xie W, Guruprasad P, Kim KH, Chun I, Angelos MG, Pajarillo R, Hong SJ, Lee YG, Shestova O, Shaw C, Cohen I, Gupta A, Vu T, Qian D, Yang S, Nimmagadda A, Snook AE, Siciliano N, Rotolo A, Inamdar A, Harris J, Ugwuanyi O, Wang M, Carturan A, Paruzzo L, Chen L, Ballard HJ, Blanchard T, Xu C, Abdel-Mohsen M, Gabunia K, Wysocka M, Linette GP, Carreno B, Barrett DM, Teachey DT, Posey AD, Powell DJ Jr, Sauter CT, Pileri S, Pillai V, Scholler J, Rook AH, Schuster SJ, Barta SK, Porazzi P, Ruella M. : CD5 deletion enhances the antitumor activity of adoptive T cell therapies Sci Immunol 9(97) : eadn6509, Jul 2024
  • Emens LA, Romero PJ, Anderson AC, Bruno TC, Capitini CM, Collyar D, Gulley JL, Hwu P, Posey AD Jr, Silk AW, Wargo JA. : Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision J Immunother Cancer 12(6) : e009063, Jun 2024
  • Sosnoski HM, Posey AD Jr. : Therapeutic intersections: Expanding benefits of CD19 CAR T cells from cancer to autoimmunity Cell Stem Cell 31 : 437-438, Apr 2024
  • Dagher OK, Posey AD Jr. : Forks in the road for CAR T and CAR NK cell cancer therapies Nat Immunol : 1994-2007, Dec 2023
  • Aasted MKM, Groen AC, Keane JT, Dabelsteen S, Tan E, Schnabel J, Liu F, Lewis HS, Theodoropulos C, Posey AD, Wandall HH. : Targeting Solid Cancers with a Cancer-Specific Monoclonal Antibody to Surface Expressed Aberrantly O-glycosylated Proteins Mol Cancer Ther 22 : 1204-1214, Oct 2023
  • Watanabe K, Gomez AM, Kuramitsu S, Siurala M, Da T, Agarwal S, Song D, Scholler J, Rotolo A, Posey AD, Rook AH, Haun PL, Ruella M, Young RM, June CH. : Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma Blood Adv 7 : 3416-3430, Jul 2023
  • Dagher OK, Schwab RD, Brookens SK, Posey AD Jr. : Advances in cancer immunotherapies Cell 186 : 1814-1814, Apr 2023
  • Brookens SK, Posey AD Jr. : Chimeric Antigen Receptor T-Cell Therapy: Current Perspective on T Cell-Intrinsic, T Cell-Extrinsic, and Therapeutic Limitations Cancer J : 28-33, Jan 2023